A recent study reveals that individuals who discontinue new weight-loss injections like Wegovy and Mounjaro can put back on shed pounds far faster than those who stop traditional lifestyle plans.
Findings released in a leading medical journal shows that while obese individuals frequently drop substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing such treatments must be cognizant of the danger of fast weight regain when the medication concludes," warns expert Dr. Susan Jebb.
Such speed of recovery suggests a reversion to starting weight within about one and a half years.
Weighing Treatments
The research, which examined 37 of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with older methods.
Researchers note that people who shed pounds through lifestyle changes alone typically see a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Fast Rebound
Doctors propose the mode of action of the jabs accounts for the heightened regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production may cause the body to produce less of its endogenous GLP-1, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Condition?
The NHS advise the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, given the significant potential of weight regain, the therapy might need to be ongoing.
This opinion is echoed by drug manufacturers, who state that the findings "underscore the chronic nature of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Users who have discontinued the jabs describe a intense resurgence of hunger.
"It was like something activating and you become starving," recalled one woman.
This challenge is compounded if users have not adopted lasting lifestyle or habit modifications during treatment.
Significant Use
Figures show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle support.
